Next Article in Journal
Application of Machine Learning Techniques to Analyze Patient Returns to the Emergency Department
Previous Article in Journal
Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

Postulated Adjuvant Therapeutic Strategies for COVID-19

Fagron. Lichtenauerlaan 182, 3062 Rotterdam, The Netherlands
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(3), 80;
Received: 3 July 2020 / Revised: 31 July 2020 / Accepted: 2 August 2020 / Published: 5 August 2020
The number of COVID-19 patients is still growing exponentially worldwide due to the high transmissibility of the SARS-CoV-2 virus. Therapeutic agents currently under investigation are antiviral drugs, vaccines, and other adjuvants that could relieve symptoms or improve the healing process. In this review, twelve therapeutic agents that could play a role in prophylaxis or improvement of the COVID-19-associated symptoms (as add-on substances) are discussed. Agents were identified based on their known pharmacologic mechanism of action in viral and/or nonviral fields and are postulated to interact with one or more of the seven known mechanisms associated with the SARS-CoV-2 virus: (i) regulation of the immune system; (ii) virus entrance in the cell; (iii) virus replication; (iv) hyperinflammation; (v) oxidative stress; (vi) thrombosis; and (vii) endotheliitis. Selected agents were immune transfer factor (oligo- and polypeptides from porcine spleen, ultrafiltered at <10 kDa; Imuno TF®), anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis; Miodesin®), zinc, selenium, ascorbic acid, cholecalciferol, ferulic acid, spirulina, N-acetylcysteine, glucosamine sulfate potassium hydrochloride, trans-resveratrol, and maltodextrin-stabilized orthosilicic acid (SiliciuMax®). This review gives the scientific background on the hypothesis that these therapeutic agents can act in synergy in the prevention and improvement of COVID-19-associated symptoms. View Full-Text
Keywords: COVID-19; SARS-CoV-2; coronavirus; dietary supplement; therapeutics; pharmacology; adjuvant; immunological; compounding; drug COVID-19; SARS-CoV-2; coronavirus; dietary supplement; therapeutics; pharmacology; adjuvant; immunological; compounding; drug
Show Figures

Figure 1

MDPI and ACS Style

Ferreira, A.O.; Polonini, H.C.; Dijkers, E.C.F. Postulated Adjuvant Therapeutic Strategies for COVID-19. J. Pers. Med. 2020, 10, 80.

AMA Style

Ferreira AO, Polonini HC, Dijkers ECF. Postulated Adjuvant Therapeutic Strategies for COVID-19. Journal of Personalized Medicine. 2020; 10(3):80.

Chicago/Turabian Style

Ferreira, Anderson O., Hudson C. Polonini, and Eli C.F. Dijkers. 2020. "Postulated Adjuvant Therapeutic Strategies for COVID-19" Journal of Personalized Medicine 10, no. 3: 80.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop